Maybe BUT not for long
!
View attachment 1704457European population as of 2016 = 741.4 million 16% of this figure are kids aged between 0 and 14 = 118, 624,000 x 30% respiratory related x $5 per use = almost 178 million this is the potential revenue if the whole market is captured at a minimum fee of just $5 per use.....
10% market share equals about $18 million
Adults aged 15 + = around 622 million x 30 % = about 187 million x $5 per use = 935 million of the total adult market
10% market share about $93 million
All recurring revenueThen we have management of respiratory diseases like COPD asthma etc. The lodgments of these for CE Mark are VERY Close as the double blind study was completed some time ago with flying colours from a larger test subject group of nearly 1000 odd patients with even higher accuracy recorded...
Then we have obstructive sleep apnea screening tool. The double blind results comparing home sleep tests with an off-the-shelf smartphone placed by the bedside table should be out within the next couple of weeks IMO. Previous test from a large subject group were very successful in the low 80% range comparing OSA against the Gold STANDARD - POLYSOMNOGRAPHY TEST.
Now that we have clearance for CE Mark for kids we can look forward to clearance for CE Mark for adults (lodgment for adults very close) with near certainty. I don't believe the market has factored the European adult market in yet on the basis of this move today....
We also have other markets that we can now more than likely enter on the back of obtaining this CE Mark clearance in the near term like Australia, Canada and Singapore... These are all almost shoe ins rubber stamps if you will...
CHINA is a big one!
A pilot study with a partner will most probably need to be conducted within China for CFDA. Tony Keating has been a regular visitor into China on two occasions in the last month. Doubt he's going there for the dumplings and Pekin duck. We know that it was business-related on both occasions..
Just look from this one company alone:
https://www.google.com/amp/www.asia...1503-yearonyear-in-the-first-half-of-2018?amp"As of the end of June, the registered customers of the Company reached 228 million, increased by 35.20 million compared to the end of 2017; MAU reached 48.60 million, representing a year-on-year increase of 50.9%; average daily consultations reached 531,000 in the first half of 2018, representing a year-on-year increase of 58%."
Now that we have obtained CE clearance all of the above can be tackled.. it'll take some time for all of the above I have presented to sink into the market. Once Mr market understands it the way I/we do I'm sure there will be many more people jumping in on this QuickSmart..
USA has around 900 million consultations per year relating to respiratory disease ( this market will be determined on the back of FDA clearance) we are well into 120 days since lodgment took place could be a decision here within the next couple of months ( maybe sooner depending on how many clock stoppages there were in between for our CEO to answer questions) I think ...
Remember the key takeaway here is that our company will be charging 5 to $10 per use for each respiratory related disease. No additional hardware is required. Around $20 to $50 per use of the screening tool for OSA ( still undetermined, more clarity once the final study is completed over the next couple of weeks IMO) if results come back as being outstanding our company may even consider looking at issuing a diagnostic tool rather then a screening tool for OSA...
OSA is diagnosed exactly the same way as is here in Australia so we are unlikely to require a further study in the United States...
View attachment 1704640Lots of news flow to look forward to here...
Happy Friday to all, have a good weekend... time to bust-a-move...
PARTY TIME
Cheers
Red bar
